1613271-27-4 Usage
Uses
Used in Pharmaceutical Industry:
(S)-1-((1R,2R,3aS,9aS)-2-((tert-butyldiphenylsilyl)oxy)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-1-yl)octan-3-yl acetate is used as a potential pharmaceutical compound for its possible biological activity and structural complexity, which may contribute to the development of new drugs or therapies.
Used in Chemical Research:
In the field of chemical research, (S)-1-((1R,2R,3aS,9aS)-2-((tert-butyldiphenylsilyl)oxy)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-1-yl)octan-3-yl acetate can be utilized as a starting material or a synthetic intermediate for the development of other complex organic molecules with potential applications in various industries.
Used in Material Science:
(S)-1-((1R,2R,3aS,9aS)-2-((tert-butyldiphenylsilyl)oxy)-5-methoxy-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-1-yl)octan-3-yl acetate may also find use in material science, particularly in the development of new materials with specific properties, such as improved stability, reactivity, or selectivity, due to its unique structure and functional groups.
Check Digit Verification of cas no
The CAS Registry Mumber 1613271-27-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,1,3,2,7 and 1 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1613271-27:
(9*1)+(8*6)+(7*1)+(6*3)+(5*2)+(4*7)+(3*1)+(2*2)+(1*7)=134
134 % 10 = 4
So 1613271-27-4 is a valid CAS Registry Number.
1613271-27-4Relevant academic research and scientific papers
AMINE SALTS OF A PROSTACYCLIN ANALOG
-
Paragraph 0398; 0399, (2015/06/03)
The present invention provides amine salts of the prostacyclin analogue of Formula I and processes for generating these amine salts.
METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG
-
Paragraph 0419-0420, (2014/06/24)
The present invention provides processes for preparing a prostacyclin analogue of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R10 is a linear or branched C1-6 alkyl. The processes of the present invention comprise steps that generate improved yields and fewer byproducts than traditional methods. The processes of the present invention employ reagents (e.g., the oxidizing reagent) that are less toxic that those used in the traditional methods (e.g., oxalyl chloride). Many of the processes of the present invention generate intermediates with improved e.e. and chemical purity; thereby eliminating the need of additional chromatography steps. And, the processes of the present invention are scalable to generate commercial quantities of the final compound.
